BACKGROUND: A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series. METHODS: Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg/m2 b.i.d. and TMZ 135 mg/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity. RESULTS: Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n = 1), grade 3 maculopapular rash (n = 2), and grade 3 nervous system disorder (generalized neurologic deterioration) (n = 1). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively. CONCLUSION: Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG. TRIAL REGISTRATION: NCT01514201.
BACKGROUND: A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series. METHODS: Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg/m2 b.i.d. and TMZ 135 mg/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity. RESULTS: Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n = 1), grade 3 maculopapular rash (n = 2), and grade 3 nervous system disorder (generalized neurologic deterioration) (n = 1). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively. CONCLUSION: Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG. TRIAL REGISTRATION: NCT01514201.
Authors: Minesh P Mehta; Ding Wang; Fen Wang; Lawrence Kleinberg; Anthony Brade; H Ian Robins; Aruna Turaka; Terri Leahy; Diane Medina; Hao Xiong; Nael M Mostafa; Martin Dunbar; Ming Zhu; Jane Qian; Kyle Holen; Vincent Giranda; Walter J Curran Journal: J Neurooncol Date: 2015-02-15 Impact factor: 4.130
Authors: Jack M Su; Patrick Thompson; Adekunle Adesina; Xiao-Nan Li; Lindsay Kilburn; Arzu Onar-Thomas; Mehmet Kocak; Brenda Chyla; Evelyn McKeegan; Katherine E Warren; Stewart Goldman; Ian F Pollack; Maryam Fouladi; Alice Chen; Vincent Giranda; James Boyett; Larry Kun; Susan M Blaney Journal: Neuro Oncol Date: 2014-06-07 Impact factor: 12.300
Authors: Yevgen Chornenkyy; Sameer Agnihotri; Man Yu; Pawel Buczkowicz; Patricia Rakopoulos; Brian Golbourn; Livia Garzia; Robert Siddaway; Stephie Leung; James T Rutka; Michael D Taylor; Peter B Dirks; Cynthia Hawkins Journal: Mol Cancer Ther Date: 2015-09-08 Impact factor: 6.261
Authors: Tina Young Poussaint; Mehmet Kocak; Sridhar Vajapeyam; Roger I Packer; Richard L Robertson; Russell Geyer; Daphne Haas-Kogan; Ian F Pollack; Gilbert Vezina; Robert Zimmerman; Soonmee Cha; Zoltan Patay; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2011-02-04 Impact factor: 12.300
Authors: Julie Sesen; Jessica Driscoll; Alexander Moses-Gardner; Darren B Orbach; David Zurakowski; Edward R Smith Journal: Front Neurol Date: 2021-04-01 Impact factor: 4.003